Context Therapeutics Inc (CNTX) - Net Assets
Based on the latest financial reports, Context Therapeutics Inc (CNTX) has net assets worth $73.17 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($79.23 Million) and total liabilities ($6.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read CNTX total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $73.17 Million |
| % of Total Assets | 92.36% |
| Annual Growth Rate | 28.13% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 318.4 |
Context Therapeutics Inc - Net Assets Trend (2016–2024)
This chart illustrates how Context Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Context Therapeutics Inc (CNTX) total assets for the complete picture of this company's asset base.
Annual Net Assets for Context Therapeutics Inc (2016–2024)
The table below shows the annual net assets of Context Therapeutics Inc from 2016 to 2024. For live valuation and market cap data, see Context Therapeutics Inc (CNTX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $95.27 Million | +702.51% |
| 2023-12-31 | $11.87 Million | -65.85% |
| 2022-12-31 | $34.76 Million | -28.00% |
| 2021-12-31 | $48.27 Million | +385.28% |
| 2020-12-31 | $-16.92 Million | +29.38% |
| 2019-12-31 | $-23.96 Million | -140.64% |
| 2017-12-31 | $58.95 Million | +349.50% |
| 2016-12-31 | $13.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Context Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2197469400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $89.70K | 0.09% |
| Other Components | $189.96 Million | 199.40% |
| Total Equity | $95.27 Million | 100.00% |
Context Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Context Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
EMS Limited
NSE:EMSLIMITED
|
$208.57 Million |
|
Xiongan Kerong Environment Technology Co Ltd
SHE:300152
|
$208.61 Million |
|
BEXIMCO PHARMA.GDR REGS 1
F:R2WA
|
$208.62 Million |
|
AIRA Capital Public Company Limited
BK:AIRA
|
$208.64 Million |
|
Huons Co. Ltd
KQ:243070
|
$208.46 Million |
|
Kejuruteraan Asastera Bhd
KLSE:0193
|
$208.46 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
$208.38 Million |
|
Atrium Therapeutics, Inc. Common Stock
NASDAQ:RNA
|
$208.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Context Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,871,020 to 95,266,262, a change of 83,395,242 (702.5%).
- Net loss of 26,725,104 reduced equity.
- New share issuances of 109,293,747 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.73 Million | -28.05% |
| Share Issuances | $109.29 Million | +114.72% |
| Other Changes | $826.60K | +0.87% |
| Total Change | $- | 702.51% |
Book Value vs Market Value Analysis
This analysis compares Context Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-2.19 | $2.27 | x |
| 2020-12-31 | $-1.54 | $2.27 | x |
| 2021-12-31 | $17.03 | $2.27 | x |
| 2022-12-31 | $2.18 | $2.27 | x |
| 2023-12-31 | $0.74 | $2.27 | x |
| 2024-12-31 | $1.63 | $2.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Context Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -28.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-28.05%) is above the historical average (-77.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -287.24% | 0.00% | 0.00x | 1.83x | $-38.98 Million |
| 2017 | -41.75% | 0.00% | 0.00x | 1.16x | $-30.51 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.09 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $8.34 Million |
| 2021 | -21.66% | 0.00% | 0.00x | 1.06x | $-15.28 Million |
| 2022 | -42.68% | 0.00% | 0.00x | 1.09x | $-18.31 Million |
| 2023 | -201.87% | 0.00% | 0.00x | 1.35x | $-25.15 Million |
| 2024 | -28.05% | 0.00% | 0.00x | 1.03x | $-36.25 Million |
Industry Comparison
This section compares Context Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Context Therapeutics Inc (CNTX) | $73.17 Million | -287.24% | 0.08x | $208.57 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Context Therapeutics Inc
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the developm… Read more